Reuters logo
BRIEF-aTyr Pharma provides additional data for resolaris phase 1b/2 trial in adult patients with facioscapulohumeral muscular dystrophy
October 6, 2016 / 1:36 PM / a year ago

BRIEF-aTyr Pharma provides additional data for resolaris phase 1b/2 trial in adult patients with facioscapulohumeral muscular dystrophy

Oct 6 (Reuters) - aTyr Pharma Inc :

* aTyr Pharma says additional data for resolaris phase 1b/2 trial in adult patients with facioscapulohumeral muscular dystrophy

* Additional data for resolaris will be released later this year

* Over dose, duration studied, resolaris was generally safe in adult patients with fshd, was generally well tolerated with exception of 1 patient

* Patients in cohorts 2 and 3 were allowed to enroll in long-term extension study (005) for which co expects to provide an update in december Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below